Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ TransplantationA Total of 10 Studies will be Conducted in ...

In 2021, Kamada acquired CYTOGAM from its previous owner, and in 2023 the company received approval from the U.S. Food and Drug Administration for the manufacturing of the product.

FDA Approval Currently Expected by Mid-2023Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50%Ability to Manufacture CYTOGAM at Kamada’s ...

Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ Transplantation A Total of 10 Studies will be Conducted in ...

Amir London, Kamada's CEO, said: "We plan to initiate commercial manufacturing of CYTOGAM at our Israeli facility in the second half of this year upon receipt of FDA approval, ...

About CYTOGAM®CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) is indicated for the prophylaxis of cytomegalovirus disease associated with the transplantation of the ...

DETROIT, MICHIGAN - June 6, 2025 (NEWMEDIAWIRE) - Cytomegalovirus (CMV) is a common virus that most adults are exposed to at some point in their lives, and over half of American adults have been ...

CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) is indicated for the prophylaxis of cytomegalovirus disease associated with the transplantation of the kidney, ...

Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ Transplantation; A Total of 10 Studies will be Conducted in ...

Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ TransplantationA Total of 10 Studies will be Conducted in ...